Data reported here suggest that in view of the massive activation of autocrine and paracrine PDGFr-β signaling pathways, some stroma-directed therapies may have minimal or no benefit in pancreatic cancer. This evidence concerns the gene PDGFRB and pancreatic neoplasm.